Adapting a point of use test card, the chemopad, for protecting chemotherapy drug quality in sub-saharan africa project summary/abstract goal: validate a new technology for detecting bad quality…
Active Cooperative Agreement Awarded Last action
- Award ID
- U01CA269195
- Recipient
-
University Of Notre Dame DU Lac UEI FPU6XGFXMBE9 Part of University Of Notre Dame DU Lac
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,300,820
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 84% complete
- Place of performance
- Notre Dame, IN 46556, USA
Award details come from USAspending.gov.
Description
Adapting a point of use test card, the chemopad, for protecting chemotherapy drug quality in sub-saharan africa project summary/abstract goal: validate a new technology for detecting bad quality chemotherapy products at the point of use. Motivation: chemotherapy medicines form the backbone of affordable cancer treatment in low- and middle- income countries (lmics), yet lmics often lack technical and regulatory capacity to evaluate the quality of chemotherapy products. There is currently no commercial technology to screen for bad quality chemotherapy products at the point of use in lmic settings, and the drug regulators in ethiopia, malawi, kenya, and cameroon do not conduct post-market surveillance testing on chemotherapy products. Activities: the technology that will be validated, called spotcheck, consists of an inexpensive paper test card (the chemopad) and a cell phone APP. We will first adapt the chemopad to screen eight types of injectable chemotherapy drugs. The phone APP's neural network will be trained to identify products that are falsified or contain less than 65% of the stated API content. Clinical, academic, and supply chain partners in ethiopia, malawi, cameroon, and kenya will conduct annual situation awareness and quality surveys of 320 chemotherapy products per year; the results will enable a team of researchers at u. North carolina to model the markets for chemotherapy products and evaluate the cost-effectiveness of the spotcheck system. After a technical performance milestone is passed, we will tailor the clinical validation of spotcheck to suit the local needs, clinical workflows, and regulatory capacity in each site. The validation of the spotcheck system will proceed through a planning and ethical approval milestone (Y3 in ethiopia and malawi and Y4 in kenya and cameroon) and three clinical phases: proficiency study, clinical validation, and implementation pilot. Proficiency testing will demonstrate that oncology pharmacists and nurses can use spotcheck with accuracy >85% to detect SF products. Clinical validation will establish whether spotcheck works correctly in a clinical setting on authentic products, rather than proficiency samples. The implementation pilot study will probe spotcheck's ability to test the drops left over in product vials after patient treatments are prepared in the hospital; this method of use would allow sustainable implementation of spotcheck in many hospitals and clinics in low-resource settings. Technology transfer efforts will empower lmic partners to produce the chemopad locally and integrate the cell phone APP into regulatory reporting systems. Impact: this project will help to fill the huge evidence GAP about the quality of chemo drugs in lmics, make IT harder for manufacturers and distributors to sell bad quality products, and improve the quality of products that are used to treat patients in lmics. 1
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $423,268 | |
| Amendment | $468,026 | |
| Amendment | $156,500 | |
| Amendment | $448,376 | |
| Amendment | $448,376 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $461,516 | |
| Amendment | $461,516 | |
| Amendment | $461,516 | |
| Amendment | $485,863 | |
| Original award | $485,863 |
Show all 15
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| S-3 Research LLC | $240,166 | |
| Clinton Health Access Initiative, Inc. | $207,696 | |
| Addis Ababa University | $281,310 | |
| Lilongwe Medical Relief Fund Trust | $162,995 | |
| MOI Teaching And Referral Hospital | $61,850 | |
| University Of North Carolina At Chapel Hill | $403,805 |
Quick answers
Who received award U01CA269195?
U01CA269195 was awarded to University Of Notre Dame DU Lac by National Cancer Institute (National Institutes of Health) on August 23, 2022.
How much is award U01CA269195 worth?
$4,300,820 has been obligated on U01CA269195.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award